BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

814 related articles for article (PubMed ID: 31175983)

  • 21. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
    Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
    Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gangliosides, α-Synuclein, and Parkinson's Disease.
    Ledeen RW; Wu G
    Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic mild stress accelerates the progression of Parkinson's disease in A53T α-synuclein transgenic mice.
    Wu Q; Yang X; Zhang Y; Zhang L; Feng L
    Exp Neurol; 2016 Nov; 285(Pt A):61-71. PubMed ID: 27637804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduction of Lewy Body Pathology by Oral Cinnamon.
    Raha S; Dutta D; Roy A; Pahan K
    J Neuroimmune Pharmacol; 2021 Sep; 16(3):592-608. PubMed ID: 32889602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP.
    Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K
    J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
    Gan L; Vargas MR; Johnson DA; Johnson JA
    J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell senescence induced by toxic interaction between α-synuclein and iron precedes nigral dopaminergic neuron loss in a mouse model of Parkinson's disease.
    Shen QQ; Jv XH; Ma XZ; Li C; Liu L; Jia WT; Qu L; Chen LL; Xie JX
    Acta Pharmacol Sin; 2024 Feb; 45(2):268-281. PubMed ID: 37674042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Plant Model of
    Kurepa J; Bruce KA; Gerhardt GA; Smalle JA
    Appl Biosci (Basel); 2024 Jun; 3(2):233-249. PubMed ID: 38835931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.
    García-Revilla J; Boza-Serrano A; Jin Y; Vadukul DM; Soldán-Hidalgo J; Camprubí-Ferrer L; García-Cruzado M; Martinsson I; Klementieva O; Ruiz R; Aprile FA; Deierborg T; Venero JL
    Acta Neuropathol; 2023 Jul; 146(1):51-75. PubMed ID: 37202527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
    Schell H; Hasegawa T; Neumann M; Kahle PJ
    Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
    Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
    Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration.
    Wang X; Becker K; Levine N; Zhang M; Lieberman AP; Moore DJ; Ma J
    Acta Neuropathol Commun; 2019 Mar; 7(1):41. PubMed ID: 30871620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.
    Sirabella R; Sisalli MJ; Costa G; Omura K; Ianniello G; Pinna A; Morelli M; Di Renzo GM; Annunziato L; Scorziello A
    Cell Death Dis; 2018 Jun; 9(7):725. PubMed ID: 29941946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease.
    Akrioti E; Karamitros T; Gkaravelas P; Kouroupi G; Matsas R; Taoufik E
    Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.